Form D · Biotechnology
Stasys Medical Corp.
Kirkland, WA · CIK 0001632952
Offering snapshot reported Jun 7, 2017 · SEC filing
- Reported sold
- $1.25M Offering amount: $2M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 24, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 7, 2017 | Initial | $1,253,107 | No comparison | 3 | SEC filing |
| Feb 13, 2015 | Initial | $160,466 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-288207
Source: Form D, filed Jun 7, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Barry | Director, Promoter |
| Mark Dye | Director |
| Chris Igielski | Director |
| Michael Rackley | Director, Executive |
| Linden Rhoads | Director |
| Nathan Sniadecki | Director, Promoter |
| Nathan White | Promoter |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
13608 88 Th Pl Ne
Kirkland, WA, 980334
Kirkland, WA, 980334